Tack Hsin-B (02526): Hong Kong public offering oversubscribed by 1073.37 times. The final offering price is HKD 99 per share.
Deutsche B(02526) announced the results of its share distribution. The company globally sold 7.9992 million H shares, with 10% sold publicly in Hong Kong and 90% internationally. The final sale price was 99 Hong Kong dollars per share, raising approximately 720 million Hong Kong dollars. Each lot consisted of 50 H shares, and trading is expected to begin on the Hong Kong Stock Exchange on Monday, March 30, 2026 at 9:00 AM.
Debt Yang-B (02526) announced the distribution results, with a total of 7.9992 million H shares sold globally. The public offering in Hong Kong accounts for 10%, while the international offering accounts for 90%. The final offering price is HK$99 per share, with a total net fundraising of approximately 720 million Hong Kong dollars. Each lot consists of 50 H shares, and it is expected that the H shares will start trading on the Hong Kong Stock Exchange on Monday, March 30, 2026, at 9:00 a.m.
The public offering in Hong Kong was oversubscribed by 1073.37 times, while the international offering was oversubscribed by 3.45 times.
Related Articles

TIANJINPORT DEV (03382) releases annual performance results, with a shareholder net profit of HK$667 million, a decrease of 3.4% year-on-year.

REMEGEN (09995) released its annual performance, with a net profit attributable to shareholders of 710 million yuan, turning losses into profits year-on-year.

PROSPER FUTURE (01259) announced its performance for the year 2025, with a net loss attributable to shareholders of approximately HK$73.209 million, representing an increase of 36.26% year-on-year.
TIANJINPORT DEV (03382) releases annual performance results, with a shareholder net profit of HK$667 million, a decrease of 3.4% year-on-year.

REMEGEN (09995) released its annual performance, with a net profit attributable to shareholders of 710 million yuan, turning losses into profits year-on-year.

PROSPER FUTURE (01259) announced its performance for the year 2025, with a net loss attributable to shareholders of approximately HK$73.209 million, representing an increase of 36.26% year-on-year.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


